Randomized trial of 2 dosages of prophylactic granulocyte–colony‐stimulating factor after induction chemotherapy in pediatric acute myeloid leukemia

摘要: BACKGROUND: Granulocyte–colony-stimulating factor (G-CSF) is effective in accelerating neutrophil recovery after intensive chemotherapy for acute myeloid leukemia (AML). However, the optimal G-CSF dosage patients with AML has not been determined. To authors' knowledge, dosages have compared a randomized study. METHODS: Patients who were enrolled on St. Jude AML97 protocol and remained study window therapy eligible to participate. The effect of given induction Courses 1 2 was analyzed 46 assigned randomly double-blinded manner receive either 5 μg/kg daily or 10 G-CSF. number days treatment, neutropenia (an absolute count <0.5 × 109/L), hospitalization; episodes febrile neutropenia, grade through 4 infection, antimicrobial therapy; transfusion requirements; cost supportive care; survival between arms. RESULTS: No statistically significant differences observed arms any endpoints measured. CONCLUSIONS: The higher (10 daily) offered no greater benefit than lower (5 receiving AML. Cancer 2011. © 2010 American Society.